Literature DB >> 16737707

DNAse treatment following thawing of cryopreserved PBMC is a procedure suitable for lymphocyte functional studies.

Alfonso J García-Piñeres1, Allan Hildesheim, Marcus Williams, Matthew Trivett, Susan Strobl, Ligia A Pinto.   

Abstract

Testing freshly isolated PBMC is not practical for immune monitoring analysis in large clinical trials or natural history studies. Thus, cryopreserved PBMC represent a more practical alternative. However, cell clumping is a common problem following thawing of PBMC isolated from blood that was previously transported and stored. Cell clumping leads to loss of cells, and could affect cell function and/or phenotype. The development and validation of procedures that prevent cell clumping and preserve cell function and surface marker expression levels are necessary to allow evaluation of immune function and phenotype in cryopreserved samples from clinical studies. The incorporation of a DNAse treatment step in the standard thawing procedure efficiently avoided clump formation, and did not result in detectable changes in cell viability, expression of standard leukocyte surface markers or two key parameters of immune function, proliferation and cytokine induction in response to a variety of common stimuli. Therefore, this procedure seems suitable for standard immunologic assays.

Mesh:

Substances:

Year:  2006        PMID: 16737707     DOI: 10.1016/j.jim.2006.04.004

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  6 in total

1.  Alterations of T-cell surface markers in older women with persistent human papillomavirus infection.

Authors:  Ana Cecilia Rodríguez; Alfonso J García-Piñeres; Allan Hildesheim; Rolando Herrero; Matthew Trivett; Marcus Williams; Ivannia Atmella; Margarita Ramírez; Maricela Villegas; Mark Schiffman; Robert Burk; Enrique Freer; José Bonilla; Concepción Bratti; Ligia A Pinto
Journal:  Int J Cancer       Date:  2011-02-01       Impact factor: 7.396

Review 2.  CAR-T Cell Therapies From the Transfusion Medicine Perspective.

Authors:  Andrew Fesnak; ChieYu Lin; Don L Siegel; Marcela V Maus
Journal:  Transfus Med Rev       Date:  2016-03-28

Review 3.  Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society.

Authors:  R Mallone; S I Mannering; B M Brooks-Worrell; I Durinovic-Belló; C M Cilio; F S Wong; N C Schloot
Journal:  Clin Exp Immunol       Date:  2010-10-05       Impact factor: 4.330

4.  Immunophenotyping of Peripheral Blood Mononuclear Cells in Septic Shock Patients With High-Dimensional Flow Cytometry Analysis Reveals Two Subgroups With Differential Responses to Immunostimulant Drugs.

Authors:  Ya Wang; Brian Gloss; Benjamin Tang; Suat Dervish; Brigitte Santner-Nanan; Christina Whitehead; Kristy Masters; Kristen Skarratt; Sally Teoh; Stephen Schibeci; Nicole Fewings; Chrystelle Brignone; Frederic Triebel; David Booth; Anthony McLean; Marek Nalos
Journal:  Front Immunol       Date:  2021-03-22       Impact factor: 7.561

5.  Loss-of-function mutations in the IL-21 receptor gene cause a primary immunodeficiency syndrome.

Authors:  Daniel Kotlarz; Natalia Ziętara; Gulbu Uzel; Thomas Weidemann; Christian J Braun; Jana Diestelhorst; Peter M Krawitz; Peter N Robinson; Jochen Hecht; Jacek Puchałka; E Michael Gertz; Alejandro A Schäffer; Monica G Lawrence; Lela Kardava; Dietmar Pfeifer; Ulrich Baumann; Eva-Doreen Pfister; Eric P Hanson; Axel Schambach; Roland Jacobs; Hans Kreipe; Susan Moir; Joshua D Milner; Petra Schwille; Stefan Mundlos; Christoph Klein
Journal:  J Exp Med       Date:  2013-02-25       Impact factor: 14.307

6.  Evaluation of peripheral blood mononuclear cell processing and analysis for Survival Motor Neuron protein.

Authors:  Dione T Kobayashi; Douglas Decker; Phillip Zaworski; Karen Klott; Julie McGonigal; Nabil Ghazal; Laurel Sly; Brett Chung; James Vanderlugt; Karen S Chen
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.